Dexcom's Trading Volume Surges 135% to $477 Million, Ranked 207th in Market Despite Revenue Growth and Share Repurchase Program
1min read On May 1, 2025, Dexcom's trading volume reached $477 million, marking a 135.06% increase from the previous day, placing it 207th in the day's stock market rankings. Dexcom's stock price fell by 1.57%.
Dexcom reported its first-quarter 2025 financial results, highlighting a 14% year-over-year revenue growth to $4.60 billion. The company also announced a $750 million share repurchase program, aiming to enhance shareholder value. This program is part of Dexcom's strategy to return capital to investors and support its stock price.
Despite the revenue growth, Dexcom's net income for the quarter decreased to $105.4 million, or $0.27 per share, compared to $146.4 million, or $0.36 per share, in the same period last year. The company attributed this decline to incremental costs and other factors affecting its bottom line. However, adjusted earnings per share remained stable at $0.32, reflecting the company's efforts to manage expenses and maintain profitability.
Ask Aime: "Is Dexcom's stock a buy after its 135% volume surge and $750M repurchase program?"
Dexcom's strong U.S. sales drove its revenue performance, with U.S. revenue growing by 15% year-over-year. International revenue also contributed to the overall growth, increasing by 7%. The company's non-GAAP gross profit margin guidance was updated to reflect these incremental costs, demonstrating its commitment to transparency and accurate financial reporting.
